<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076438</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2012002450</org_study_id>
    <secondary_id>Grant# PC 14-13</secondary_id>
    <nct_id>NCT02076438</nct_id>
  </id_info>
  <brief_title>Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease in Hospitalized Adults-A Double Blind Placebo Controlled Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Peters University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate if administration of probiotic Culturelle (Lactobacillus Rhamnosus
      GG) along with antibiotics can help decrease the occurrence of diarrhea caused by
      antibiotics as well as Clostridium difficile Diarrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inpatient adult males and females who are at least 18 years of age or older, undergoing
      treatment with antibiotics irrespective of indication and the type of antibiotics. The
      setting is an academic hospital.The  patients are screened and potentially recruited upon
      initiation of antibiotic treatment regardless of indication for antibiotic prescription. The
      participants are patients being admitted to any inpatient units of the hospital for
      treatment with antibiotics. Exclusion criteria is:

        -  Diarrhea on admission or within the preceding week

        -  Reported recurrent diarrhea

        -  Bowel pathology that could result in diarrhea (including preexisting Inflammatory Bowel
           disease{IBD}, all forms for colitis or any other condition resulting in preexisting
           diarrhea)

        -  Intake of high risk antibiotics (clindamycin, cephalosporins, aminopenicillins→ well
           known to cause CDAD) and or more than two courses of other antibiotics in the past four
           weeks to exclude pre-existing diarrhea associated with antibiotic use

        -  Immunosuppression (Chronic steroid use, Active chemotherapy, Active radiotherapy, HIV
           or any other disorder resulting in a compromise in participants immune status)

        -  Bowel surgery causing liquid stools

        -  Regular probiotic intake before admission

        -  Lactose intolerance or intolerance to dairy products.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diarrhea associated with antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of probiotics</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient experience with use of probiotics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillaus Rhamnosus GG 10 billion cfu BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Randomized to receive probiotics or placebo</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Lactobacillus Rhamnosus GG 10 billion cfu bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient adult males and females who are at least 18-89 years of age,  undergoing
             treatment with antibiotics irrespective of indication and the type of antibiotics.

        Exclusion Criteria:

          -  Diarrhea on admission or within the preceding week

          -  Reported recurrent diarrhea

          -  Bowel pathology that could result in diarrhea (including preexisting Inflammatory
             Bowel disease{IBD}, all forms for colitis or any other condition resulting in
             preexisting diarrhea)

          -  Intake of high risk antibiotics (clindamycin, cephalosporins, aminopenicillins→ well
             known to cause CDAD) and or more than two courses of other antibiotics in the past
             four weeks to exclude pre-existing diarrhea associated with antibiotic use

          -  Immunosuppression (Chronic steroid use, Active chemotherapy, Active radiotherapy, HIV
             or any other disorder resulting in a compromise in participants immune status)

          -  Bowel surgery causing liquid stools

          -  Regular probiotic intake before admission

          -  Lactose intolerance or intolerance to dairy products
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amita Avadhani, DNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University and Saint Peters University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Peters University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amita Avadhani, DNP</last_name>
      <phone>732-745-8600</phone>
      <phone_ext>8073</phone_ext>
      <email>aavadhani@saintpetersuh.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Zaidi, BA</last_name>
      <phone>7327458600</phone>
      <phone_ext>8029</phone_ext>
      <email>nzaidi@saintpetersuh.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Alcid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amar Bukhari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Caldwell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Kamienski, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Amita Avadhani, DNP, DCC, ACNP, ANP, CCRN</investigator_full_name>
    <investigator_title>Assistant Professor/Track coordinator</investigator_title>
  </responsible_party>
  <keyword>antibiotics</keyword>
  <keyword>diarrhea</keyword>
  <keyword>c diff</keyword>
  <keyword>Hospitalized patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
